[Precursor lesions of type II endometrial cancer: diagnostic criteria and pathogenesis].
Wang
Hui-jun
HJ
Department of Pathology, University of Arizona, AZ 85724, USA.
Zheng
Wen-xin
WX
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002278:Carcinoma in Situ / Q000473:pathology; D018283:Cystadenocarcinoma, Papillary / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D018284:Cystadenocarcinoma, Serous / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D018450:Disease Progression; D004714:Endometrial Hyperplasia / Q000473:pathology; D016889:Endometrial Neoplasms / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D017239:Paclitaxel / Q000008:administration & dosage; D011230:Precancerous Conditions / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D014594:Uterine Neoplasms / Q000473:pathology*
D016190:Carboplatin; D017239:Paclitaxel